OMNITROPE Drug Profile

Summary for Tradename: OMNITROPE

High Confidence Patents:	7
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for OMNITROPE
Recent Clinical Trials:	See clinical trials for OMNITROPE

See drug prices for OMNITROPE

Recent Clinical Trials for OMNITROPE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1
Albert Einstein College of Medicine	Phase 1
Columbia University	Phase 1

See all OMNITROPE clinical trials

Pharmacology for OMNITROPE

Established Pharmacologic Class	Recombinant Human Growth Hormone
Chemical Structure	Human Growth Hormone

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for OMNITROPE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for OMNITROPE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	12,161,843	2039-05-23	DrugPatentWatch analysis and company disclosures
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	5,567,677	2013-10-22	DrugPatentWatch analysis and company disclosures
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	5,763,394	2015-06-09	DrugPatentWatch analysis and company disclosures
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	5,981,485	2017-07-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for OMNITROPE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	10,016,338	2036-12-20	Patent claims search
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	10,045,943	2036-04-08	Patent claims search
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	10,154,856	2034-02-06	Patent claims search
Sandoz Inc.	OMNITROPE	somatropin	For Injection	021426	10,335,463	2037-11-28	Patent claims search

International Patents for OMNITROPE

Country	Patent Number	Estimated Expiration
Australia	2019273831
Australia	2019273832
Australia	2019273833
Australia	2019273834

Supplementary Protection Certificates for OMNITROPE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
LUC00256	Luxembourg		PRODUCT NAME: LONAPEGSOMATROPINE; AUTHORISATION NUMBER AND DATE: EU/1/21/1607 20220117
25/2022	Austria		PRODUCT NAME: LONAPEGSOMATROPIN; REGISTRATION NO/DATE: EU/1/21/1607 (MITTEILUNG) 20220117
SPC/GB22/023	United Kingdom		PRODUCT NAME: LONAPEGSOMATROPIN; REGISTERED: UK EU/1/21/1607(FOR NI) 20220117; UK FURTHER MAS ON IPSUM 20220117
22C1029	France		PRODUCT NAME: LONAPEGSOMATROPINE; REGISTRATION NO/DATE: EU/1/21/1607 20220117

Market Dynamics and Financial Trajectory for OMNITROPE

Last updated: April 18, 2026

What is OMNITROPE?

OMNITROPE (somatropin [rDNA origin] injection) is a recombinant human growth hormone developed by Novo Nordisk. Approved by the FDA in 1987, it addresses growth hormone deficiency in pediatric and adult patients. The drug has diversified indications including growth failure, adult growth hormone deficiency, and off-label uses such as wasting syndromes.

Market Size and Segmentation

The global growth hormone market was valued at approximately USD 4.5 billion in 2021. It is projected to grow at a CAGR of 4.5% through 2030, reaching USD 7.6 billion. OMNITROPE holds a significant share, approximately 55%, within the biologics segment focusing on growth hormone therapies.

The pediatric segment accounts for around 60% of sales, driven by early diagnosis and treatment modalities. The adult segment, increasingly recognized, comprises about 40%. Market penetration varies across regions: North America (45% market share), Europe (35%), rest of the world (20%).

Competitive Landscape

OMNITROPE faces competition from biosimilars and alternatives developed by companies like Sandoz, Ipsen, and Thermo Fisher Scientific.

Competitor	Product Name	Estimated Market Share	Key Differentiator
Novo Nordisk	OMNITROPE	55%	Established brand, extensive pediatric approval
Sandoz	Zomacton	15%	Biosimilar, lower price points
Ipsen	-incl. Nutropin AQ	10%	Pediatric and adult indications
Others	-	20%	Emerging biosimilars and regional products

The entry of biosimilars from 2020 onward has exerted price competition, leading to revenue pressure in mature markets.

Revenue and Financial Trajectory

Current revenue for OMNITROPE approximates USD 2.470 billion (2022), representing roughly 55% of Novo Nordisk’s total sales. Growth trends show plateauing revenue in mature markets due to biosimilar competition but potential expansion in emerging markets.

Revenue Breakdown (2022)

Region	Revenue (USD billion)	Growth Rate (YOY)	Key Factors
North America	1.1	3%	Established market, shifting to biosimilars
Europe	0.85	2%	Price pressures, regulatory challenges
Asia-Pacific	0.35	10%	Expanding healthcare infrastructure
Rest of the world	0.17	5%	Increasing awareness of genetic treatments

Forecasted Trends

For 2023–2027, revenues are projected to grow at a CAGR of 3%, driven mainly by emerging markets. The potential for new indications and formulations is limited, constricted by biosimilar competition.

Pricing and Reimbursement Landscape

Pricing varies globally: North America (USD 15,000–USD 30,000 annually), Europe (USD 20,000–USD 40,000), Asia-Pacific (USD 5,000–USD 15,000). Reimbursement policies heavily influence sales volume. Some markets restrict use to severe growth deficiencies, limiting market size.

Regulatory Considerations

The approval landscape remains stable for breaching new indications for OMNITROPE with occasional expansions for adult uses. Biosimilars face regulatory hurdles, including demonstrating similarity and efficacy.

Innovation and Pipeline

No recent large-scale new molecular entities replace OMNITROPE, but ongoing research for long-acting formulations aims to extend product lifecycle. An investigational long-acting growth hormone (LB03002) shows potential, but its market entry is projected beyond 2025.

Risks and Opportunities

Risks: Biosimilar erosion, regulatory delays, pricing pressures, regional reimbursement restrictions.

Opportunities: Market expansion in Asia-Pacific, growth through new indications, development of long-acting formulations.

Key Takeaways

• OMNITROPE is a mature biologic with approximately USD 2.5 billion in annual revenue, predominantly derived from North America and Europe.
• Biosimilars from competitors have reduced the growth trajectory in developed markets; revenue growth primarily driven by emerging markets.
• The future growth depends on market expansion in Asian regions and innovation, such as long-acting formulations.
• Pricing pressures and reimbursement policies are critical determinants of revenue stability.

FAQs

1. How does biosimilar competition affect OMNITROPE's market share? Biosimilars have introduced price competition, reducing margins and threatening market dominance in mature regions.

2. Are new indications likely to impact OMNITROPE's sales? Limited immediate pipeline expansion diminishes the impact; future growth depends on long-term research investments.

3. What regional opportunities exist for growth? Asia-Pacific offers expanding markets due to increasing healthcare access and economic growth.

4. How does pricing vary internationally? Pricing is highest in North America and Europe, with significant variations based on local reimbursement policies.

5. What strategic moves could extend OMNITROPE's lifecycle? Development of long-acting formulations and expansion into new indications could enhance long-term competitiveness.

References

1. MarketWatch. (2023). Growth hormone market size and forecast. Retrieved from https://www.marketwatch.com/
2. Novo Nordisk annual report. (2022). Financial overview and product sales. Retrieved from https://www.novonordisk.com/investors/financial-reports.html
3. IQVIA. (2022). Global biologic drug landscape. Retrieved from https://www.iqvia.com/
4. Evaluate Pharma. (2022). Biosimilar market impact assessments. Retrieved from https://www.evaluate.com/
5. FDA. (2022). Regulatory guidelines for biosimilar approval. https://www.fda.gov/

---

This report identifies the current market status and future outlook for OMNITROPE, emphasizing revenue streams, competitive factors, and growth opportunities.